A case report of enzalutamide administration in a dialysis-dependent patient with castration-resistant prostate cancer

Enzalutamide, an androgen receptor signaling inhibitor, is a standard of care treatment for metastatic castration-resistant prostate cancer. We present the first reported case of enzalutamide in a patient with end-stage renal disease, on dialysis. While there were no significant toxicities, a sustained increase in systolic blood pressure was maintained after starting enzalutamide, suggestive of a degree of drug accumulation. Further evaluation of novel hormonal agents in end-stage renal disease patients should be encouraged as this population is typically excluded from clinical trials.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2017 Jan 01 [Epub ahead of print]

Erica S Tsang, Marie de Haan, Bernhard J Eigl

Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe